Endo International

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products,.

Arecor Therapeutics PLC (LON:AREC) has signed an additional agreement with an existing client to develop a new ready-to-use (RTU) product formulation for a previously intravenous product. The formulation study agreement is with Par Sterile Products, part of US company Endo International PLC (NASDAQ:ENDP), which will fund the development work.

Arecor Therapeutics expands reformulation work with Par

AYRO

Monaker Group

OMNIQ Corp

SNDL Inc.

United Wholesale Mortgage

Wipro Limited Sponsored ADR

Spending $500 is a small bet with upside potential for readers seeking penny stocks to buy. These Reddit faves show with the highest risks come the highest rewards.

7 Best Reddit Penny Stocks To Buy if You Have $500 To Spend

Endo shares are up 43% since its recommendation in April 2020. Stock is down sharply from over $10.

Endo International: Why Buy After The Drop

Endo International's (ENDP) CEO Blaise Coleman on Q1 2021 Results - Earnings Call Transcript

Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.

Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1

Endo (ENDP) delivered earnings and revenue surprises of 52.08% and 7.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Endo International (ENDP) Tops Q1 Earnings and Revenue Estimates

DUBLIN, May 6, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2021. "I am proud of the continued strong execution across each of Endo's business segments as reflected by our better than expected first-quarter 2021 results.

Endo Reports First-Quarter 2021 Financial Results And Updates 2021 Financial Guidance

TORONTO, May 3, 2021 /PRNewswire/ - Maverix Private Equity, a Toronto-based private equity firm which recently announced an inaugural USD $500 million growth-fund, has today announced the addition of Michael Wasserman as a Managing Partner, joining Founder John Ruffolo and Mark Maybank. Michael is returning to Canada after 17 years at H.I.G Capital Management, a leading global private equity investment firm with more than $44 billion of equity capital under management.

Maverix Private Equity Announces Team Additions

Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Endo International (ENDP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

DUBLIN, April 29, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that data relevant to the use of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, will be presented during The Aesthetic Meeting 2021. This data will be highlighted in two oral presentations during the virtual and in-person meeting taking place in Miami, FL April 29–May 3, 2021.

Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at The Aesthetic Meeting 2021

Mark Barberio appointed Chairman of the Board of Directors effective at 2021 Annual General Meeting DUBLIN, April 27, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo" or the "Company") today announced that Mark Barberio, who currently serves as an independent member of Endo's Board of Directors (the "Board"), has been appointed Chairman of the Board effective at the Company's 2021 Annual General Meeting. Mr. Barberio's appointment is part of Endo's ongoing Board succession process, which has also included adding two new Board members since the Company's 2020 Annual General Meeting.

Endo Implements Board Succession Plan

Johnson & Johnson

AbbVie

Teva Pharmaceutical

Four drugmakers helped cause the deadly U.S. opioid epidemic by deceptively marketing their drugs and downplaying their addictive risks, a lawyer for several California counties argued on Monday at the start of multibillion-dollar trial.

J&J, other drugmakers go to trial in California in $50 billion case over 'deadly legacy' of opioids

DUBLIN, April 13, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its first-quarter 2021 financial results on May 6, 2021 and members of its senior management team will host a conference call and webcast on May 7, 2021 at 7:30am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 5491584.

Endo to Announce First Quarter 2021 Financial Results

DUBLIN, April 13, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that Phase 3 data evaluating Qwo® (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women was published in Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery. In addition to Phase 3 studies, the publication also includes a supplemental video that demonstrates the injection techniques for QWO.

Endo Announces Publication of Phase 3 Qwo® (collagenase clostridium histolyticum-aaes) Data in Peer-Reviewed Dermatologic Surgery

DUBLIN, April 7, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced the entry of an order granting a default judgment on liability against its wholly-owned subsidiaries Endo Health Solutions Inc. (EHSI) and Endo Pharmaceuticals Inc. (EPI) in Staubus, et al. v. Purdue Pharma, L.P.

Endo Comments on Entry of Default Liability Judgment in Tennessee State Court Case

Endo (ENDP) reported earnings 30 days ago. What's next for the stock?

Why Is Endo (ENDP) Down 16.8% Since Last Earnings Report?

Valuation is a big part of security analysis. But before choosing a valuation model and begin crunching numbers, security analysts must understand how the company behind an equity security creates value.

What Creates Value, Part I: Steady-State Value

DUBLIN, March 11, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that its wholly-owned subsidiaries Endo Luxembourg Finance Company I S.à r.l. ("Endo Luxembourg") and Endo U.S. Inc. (together with Endo Luxembourg, the "Issuers") priced $1.295 billion aggregate principal amount of 6.125% senior secured notes due 2029 at an issue price of $1,000 per $1,000 principal amount in connection with its previously announced private offering, which represents an upsize of $295.0 million over the previously contemplated offering amount.

Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes

DUBLIN, March 11, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that its wholly-owned subsidiaries Endo Luxembourg Finance Company I S.à r.l. ("Endo Luxembourg") and Endo U.S. Inc. (together with Endo Luxembourg, the "Issuers") intend to offer senior secured notes, subject to market and customary conditions.

Endo International plc Announces Proposed Private Offering Of Senior Secured Notes

DUBLIN, March 4, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it has commenced a refinancing of its existing $3.3 billion senior secured term loan due 2024 with the net proceeds of a new senior secured term loan and other debt issuances. The new...

Endo International plc Commences Refinancing of its Existing Term Loan

Endo International PLC (ENDP) CEO Blaise Coleman on Q4 2020 Results - Earnings Call Transcript

Endo's (ENDP) earnings and sales beat estimates in the fourth quarter.

Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4

DUBLIN, Feb. 25, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and introduced 2021 financial guidance. "I am proud of all that the Endo team achieved in a very challenging year. We...

Endo Reports Fourth-Quarter And Full-Year 2020 Financial Results And Introduces 2021 Financial Guidance

DUBLIN, Feb. 17, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference on Monday, March 1, 2021 at 9:15 a.m. ET. A live webcast and audio archive for the...

Endo to Participate at J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference

DUBLIN, Feb. 17, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately. Ms. Chao has also been appointed to Endo's Audit Committee and its Compliance Committee and...

News for Endo International Stock (ENDP)